TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04700839
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
Study: NCT04700839
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study: NCT03891264
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
Study: NCT01778439
Drug: OMP-52M51
Normalized name: OMP-52M51
DrugBank: Brontictuzumab (DB12737)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095782
Drug: Intercalated combination of chemotherapy and erlotinib
Normalized name: combinations of levothyroxine and liothyronine
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.
Study: NCT01556425
Drug: Vivitrol
Normalized name: Vivitrol
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
Study: NCT01381848
Drug: Doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
Study: NCT01381848
Drug: Doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
Study: NCT03126695
Drug: Ticagrelor granule
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A P2Y12 receptor inhibitor provided as granule for suspension.
Study: NCT03126695
Drug: Ticagrelor pediatric tablets
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
Study: NCT03126695
Drug: Ticagrelor pediatric tablets suspended in water
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
Study: NCT03126695
Drug: Ticagrelor immediate release (IR) tablets (Commercial tablet)
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
Study: NCT02467738
Drug: Cesium-131
Normalized name: Cesium-131
DrugBank: Cesium Cs-131 (DB19250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo brachytherapy with Cesium-131
Study: NCT00787462
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Study: NCT02005419
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT02005419
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT00844415
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.14 mg/kg BID to a max 150 mg BID
Study: NCT01922687
Drug: amlodipine plus atorvastatin (Caduet)
Normalized name: amlodipine / atorvastatin
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01922687
Drug: amlodipine (Norvasc)
Normalized name: amlodipine Oral Tablet [Norvasc]
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00993265
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
Study: NCT00642395
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bortezomib-Melphalan
Study: NCT00047099
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00047099
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00047099
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00047099
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03141671
Drug: GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT03141671
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT03141671
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT03141671
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
Study: NCT03141671
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT03560973
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ramucirumab/ placebo was added to gemcitabine
Study: NCT03560973
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ramucirumab/ placebo was added to gemcitabine
Study: NCT02053857
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02782468
Drug: Pevonedistat 25 mg/m^2
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 25 mg/m\^2 intravenous infusion.
Study: NCT03910452
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
Study: NCT03910452
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
Study: NCT03910452
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
Study: NCT06395194
Drug: Cardiac outcomes on treatment with valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study: NCT06395194
Drug: Cardiac outcomes on treatment with amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study: NCT02171793
Drug: BI 1744 CL
Normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782468
Drug: Pevonedistat 44 mg/m^2
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 44 mg/m\^2 intravenous infusion.
Study: NCT02782468
Drug: Pevonedistat 10 mg/m^2
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 10 mg/m\^2 intravenous infusion.
Study: NCT02782468
Drug: Pevonedistat 20 mg/m^2
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 20 mg/m\^2 intravenous infusion.
Study: NCT02782468
Drug: Azacitidine 75 mg/m^2
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
Study: NCT04563494
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prevention of post op nausea and vomiting
Study: NCT02587650
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02587650
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02587650
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02587650
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02581202
Drug: lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet
Study: NCT02581202
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet
Study: NCT00313170
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intramuscular injection 250 mg \& 500 mg
Study: NCT00358488
Drug: GSK159797 (10, 15, and 20mcg)
Normalized name: GSK159797
DrugBank: GSK159797 (DB05043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK159797 (10, 15, and 20mcg)
Study: NCT00358488
Drug: salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol
Study: NCT01200810
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00208819
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00208819
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00208819
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00358488
Drug: salmeterol 50mcg
Normalized name: FLUTICAS 500/SALMETEROL 50MCG INHL DISK
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: salmeterol 50mcg
Study: NCT01834014
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT00208819
Drug: divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03133637
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible infants will receive ceftriaxone as standard of care for sepsis
Study: NCT01246583
Drug: Vehicle 1
Normalized name: meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 1 twice daily for 4 weeks
Study: NCT01246583
Drug: Vehicle 2
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 2 twice daily for 4 weeks
Study: NCT00151099
Drug: high caloric drink with protein
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00449501
Drug: Budesonide/formoterol pMDI
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00449501
Drug: Budesonide HFA pMDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05054114
Drug: Interferon gamma human recombinant (IFN-G)
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal form
Study: NCT00621478
Drug: lorazepam or diazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push.
Study: NCT00322283
Drug: Oglemilast
Normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oglemilast, 15mg once per day, oral administration
Study: NCT03673670
Drug: Tiotropium/olodaterol (Respimat)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anticholinergic/β-agonist combination medication
Study: NCT01038817
Drug: Duraphat
Normalized name: testosterone enanthate Injectable Solution [Durathate]
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
Study: NCT00298350
Drug: GS-9137 - A Novel HIV-1 Integrase Inhibitor
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02159950
Drug: Tasquinimod
Normalized name: Tasquinimod
DrugBank: Tasquinimod (DB05861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01638520
Drug: Pascolizumab
Normalized name: Pascolizumab
DrugBank: Pascolizumab (DB06560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
Study: NCT02116777
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02116777
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02569814
Drug: Fimasartan/Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02284126
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied powder and paste to surgical site at time of closure.
Study: NCT01125150
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage to be determined by Endocrinologist
Study: NCT01810185
Drug: Low dose naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5 mg daily for 12 weeeks
Study: NCT01316861
Drug: EMS Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMS Acarbose 50 mg 3 times a day
Study: NCT01316861
Drug: Bayer Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bayer Acarbose 50 mg 3 times a day
Study: NCT01439282
Drug: eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
Study: NCT02232802
Drug: Enoxaparin Sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of bioavailability of generic Enoxaparin Sodium and Clexane
Study: NCT00350948
Drug: Telcyta
DrugBank: Canfosfamide (DB04972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 of 28 day Cycle.
Study: NCT01183559
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
Study: NCT01183559
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC=5 days 1 and 29 during radiation therapy
Study: NCT01183559
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
Study: NCT00515801
Drug: glibenclamide
Normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glibenclamide 15 mg single dose
Study: NCT03609840
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03502733
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00603109
Drug: rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: rimonabant capsule 20 mg per day PO for 6 months
Study: NCT04599777
Drug: TACE combined with sorafenib and tislelizumab
Normalized name: Tislelizumab
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT01050309
Drug: hexaminolevulinate (HAL)
DrugBank: Hexaminolevulinate (DB06261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon